ArticleBioinformatics (Oxford, England)2026
DrugDL: dual-modal deep learning framework for multi-property drug prediction and targeted therapy discovery.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
motivationThe accurate and robust representation of drug molecule features, the prediction of drug-target biomacromolecule interactions, and the determination of physicochemical properties are crucial in drug development. However, these tasks remain challenging due to issues such as the limited generalizability of single-modal representations, the absence of multitask prediction frameworks, and weak adaptability in cold-start scenarios.
resultsIn this study, we present DrugDL, a framework for comprehensive drug molecule representation and the prediction of multiple downstream tasks, including drug-target interactions, binding affinities, binding sites, physicochemical properties, toxicity, and drug-drug interactions. DrugDL jointly learns representations of the drug chemical space and the target protein biological space, while capturing multiscale interaction mechanisms between drug molecules and target proteins through the integration of cross-modal contrastive learning and single-modal feature enhancement algorithms. Specifically, DrugDL employs a multitask prediction framework to predict multiple properties of drug molecules. In practical applications, it consistently outperforms state-of-the-art methods, particularly in cold-start tasks. The framework has been successfully applied to high-throughput screening, the identification of inhibitors of SARS-CoV-2 and metabolic enzymes, and the prediction of cancer-targeted drugs. Experimental validations on EGFR and ALK targets further demonstrate its effectiveness as a precise drug discovery tool. By enabling accurate molecular representation and multi-property prediction, DrugDL provides end-to-end technical support for drug development, thereby significantly accelerating the drug discovery process. AVAILABILITY AND IMPLEMENTATION: The datasets and code are available at https://github.com/ZhangQi9910/DrugDL. The version of record is archived in Zenodo with the DOI: 10.5281/zenodo.20579718.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.